Pfizer and China's Innovent Biologics have agreed a licensing and collaboration deal worth up to $10.5 billion, covering twelve early-stage cancer medicines. The agreement is one of the largest of its kind between a Western pharmaceutical company and a Chinese biotech, and comes as global drugmakers increase their activity in China's expanding drug development sector.

Under the financial terms, Innovent will receive $650 million upfront. The remaining value, up to $9.85 billion, is structured as milestone payments contingent on development progress, regulatory approvals and commercial outcomes. That back-loaded structure is standard for deals of this scale, where the bulk of the value depends on whether the medicines successfully clear clinical and regulatory hurdles.

The portfolio covers antibody-drug conjugates, a class of targeted cancer therapies that attach cytotoxic agents directly to tumour cells, as well as multi-specific antibodies. Eight of the twelve programmes originated with Innovent; the remaining four are early discovery programmes proposed by Pfizer. The agreement was entered into by Innovent Biologics alongside its wholly owned subsidiaries Innovent Biologics (Suzhou) and Fortvita Biologics (USA).

Development responsibilities are divided across three tiers. For four of the programmes, both companies will co-develop and co-commercialise the medicines, sharing profits in the United States and Europe while Innovent retains rights in Greater China. For another four, Pfizer receives an exclusive licence outside Greater China. The final four grant Pfizer an exclusive global licence, with Pfizer bearing all associated development costs. Across all twelve programmes, Innovent will lead development through Phase 1 clinical trials, after which Pfizer assumes responsibility for global development.

The deal reflects conditions in China's biotech sector that have shifted considerably over the past several years. The value of licensing deals involving companies in the greater China region rose nearly tenfold between 2021 and 2025, reaching $137.7 billion last year, according to data from Pharmcube. Analysts expect that figure to climb further in 2026, driven by continued international demand for assets emerging from Chinese laboratories, particularly in oncology.

Pfizer's agreement with Innovent follows a deal the company struck in May 2025 with 3SBio, a Shenyang-based drugmaker, around a cancer immunotherapy asset. Taken together, the two deals point to a deliberate approach by Pfizer to build out its oncology pipeline through Chinese partnerships rather than purely through internal research or Western acquisitions.

For Innovent, the deal provides significant capital at a relatively early stage of development, alongside access to Pfizer's global commercialisation infrastructure. For Pfizer, it secures a large volume of early-stage assets at a point when the cost of in-house drug discovery continues to rise and the pressure to replenish post-patent pipelines remains acute.

The broader pattern this deal represents is now well established. Western pharmaceutical companies are increasingly sourcing early-stage drug candidates from China, where a generation of scientists trained abroad have returned to build research-focused biotechs with lower overheads and faster trial recruitment. Whether the clinical results from this expanding wave of partnerships will match the financial ambition behind them is a question the industry has not yet answered.

‍